Relapse-Free Course in Nearly Half of Crohn’s Disease Patients With Infliximab and Plant-Based Diet as First-Line Therapy: A Single-Group Trial
Mitsuro Chiba, Tsuyotoshi Tsuji, Kunio Nakane, Satoko Tsuda, Hideo Ohno, K. Sugawara, Masafumi Komatsu, Haruhiko Tozawa
Abstract
< 0.0001). Surgical rates at 5 and 10 years were 12% and 19%, respectively. Conclusions Infliximab and plant-based diet as first-line therapy created an unprecedented relapse-free course in nearly half of patients with Crohn's disease.
Topics & Concepts
MedicineInfliximabCrohn's diseaseClinical endpointInternal medicineRandomized controlled trialDiseaseMaintenance therapySurgeryGastroenterologyChemotherapyInflammatory Bowel DiseaseGastrointestinal motility and disordersClinical Nutrition and Gastroenterology